GlassScriptPhysician profile
Georgios Papastergiou
NPI 1790054393
$2,918.58
in general payments reported to CMS, 2019-2025
23 companies · $605 in 2025
The $605 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $174 · 2021: $620 · 2022: $268 · 2023: $404 · 2024: $579 · 2025: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,588.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $750.61 | 2019-2025 | Rocklatan, Clareon, Luxor |
| Abbvie INC. | $677.78 | 2023-2025 | |
| Bausch & Lomb Americas INC. | $181.25 | 2024-2025 | Vyzulta, Miebo |
| Allergan, INC. | $176.35 | 2019-2021 | |
| Genentech USA, INC. | $151.52 | 2022-2025 | Vabysmo |
| Novartis Pharmaceuticals Corporation | $144.78 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $113.00 | 2021-2024 | Acthar |
| Astellas Pharma US INC | $101.20 | 2025 | Izervay |
| New World Medical,INC. | $91.02 | 2023 | |
| Horizon Therapeutics Plc | $85.82 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $76.75 | 2024 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $66.34 | 2020-2021 | |
| Aerie Pharmaceuticals, INC. | $60.17 | 2019-2021 | |
| Thea Pharma INC. | $53.20 | 2023-2025 | Iyuzeh |
| Sun Pharmaceutical Industries INC. | $40.26 | 2023-2025 | Cequa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $26.75 | 2022 | |
| Iridex Corporation | $18.75 | 2019 | |
| Ani Pharmaceuticals, INC. | $18.51 | 2024 | Purified Cortrophin Gel |
| Harrow Eye, LLC | $18.50 | 2024 | Vevye |
| Shire North American Group INC | $18.35 | 2019 | |
| Boston Scientific Corporation | $17.41 | 2020 | |
| Eyevance Pharmaceuticals LLC | $17.01 | 2019 | |
| Kala Pharmaceuticals, INC. | $13.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Georgios Papastergiou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.